Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers
暂无分享,去创建一个
A. Hauschild | R. Gutzmer | A. Wollenberg | B. Homey | J. Hassel | T. Dirschka | P. Gerber | E. Bölke
[1] J. Bernier,et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Enk,et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[3] A. Hauschild,et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] B. Homey,et al. Density of Demodex folliculorum in Patients Receiving Epidermal Growth Factor Receptor Inhibitors , 2011, Dermatology.
[5] K. Kudo,et al. Toxicity manifesting as cosmetic hair alterations during erlotinib treatment , 2011, Acta oncologica.
[6] M. Steinhoff,et al. Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. , 2010, Journal of the American Academy of Dermatology.
[7] M. Lacouture,et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. , 2010, Journal of the National Cancer Institute.
[8] A. Wollenberg,et al. Microbiological analysis of epidermal growth factor receptor inhibitor therapy‐associated paronychia , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] Jordi Giralt,et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.
[10] Lynne Wagner,et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group , 2010, Supportive Care in Cancer.
[11] B. Homey,et al. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Matuschek,et al. Development and Management of Severe Cutaneous Side Effects in Head-and-Neck Cancer Patients during Concurrent Radiotherapy and Cetuximab , 2008, Strahlentherapie und Onkologie.
[13] A. Rademaker,et al. Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results , 2007, Oncology.
[14] A. del Palacio,et al. Erlotinib associated with rosacea‐like folliculitis and Malassezia sympodialis , 2006, The British journal of dermatology.
[15] R. Gutzmer,et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy , 2005, The British journal of dermatology.
[16] E. Van Cutsem,et al. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] M. Kris,et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Halpern,et al. Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.
[19] F. Forton,et al. Density of Demodex folliculorum in rosacea: a case‐control study using standardized skin‐surface biopsy , 1993, The British journal of dermatology.